Stay updated with breaking news from Actrims. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such
-- Presentations will feature analyses from the pivotal Phase 3 study of UPLIZNA, including the relationship between B-cell subsets and NMOSD attacks -- Horizon Therapeutics plc (Nasdaq: HZNP) today
New real-world data show MAVENCLAD (cladribine tablets) had lower annualised relapse rates and longer time to first relapse and time to switch than fingolimod, dimethyl fumarate and teriflunomide
Phase II post-hoc data show evobrutinib reduced acute and chronic inflammation processes in the central nervous system that may be early indicators of MS disease progression Additional data
Full analysis of Phase 3b NOVA study provides insights on efficacy of every six-week dosing with natalizumab as compared to the approved every four-week dosingReal-world analysis shows significantly lower